Medical/Pharmaceuticals
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based inSouth Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, ...
2023-02-03 14:34
3440
Marc-André Pépin of Invescap Announces Significant Expansion of Clinic Network
GENEVA, Feb. 2, 2023 /PRNewswire/ -- Private lending and investment firm, Invescap, has announced an expansion of its network of clinics across the US. Maintaining its deep-rooted presence inFlorida, Invescap recently entered into agreements to finance medical clinics based inNorth Carolina, Sout...
2023-02-02 23:13
3201
Copan Diagnostics Announces Leadership Change
CARLSBAD, Calif., Feb. 2, 2023 /PRNewswire/ -- COPAN Group announces the departure ofNorman Sharples, Chief Executive Officer of Copan Diagnostics, from the Company he co-founded withDaniele Triva in 1994 and the appointment of Fabrizio Mazzocchi as new CEO and member of Copan Diagnostics' board ...
2023-02-02 23:09
5343
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
BEIJING and TORONTO, Feb. 2, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer,James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Mar...
2023-02-02 19:37
2755
Servier full year 2021/22 results confirm the transformation trajectory of the Group
* Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales * Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) * Important development...
2023-02-02 14:30
2663
SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan
TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ultrasound (HIFU)...
2023-02-02 14:00
2561
Accelerating Energy Efficiency Adoption, Deep-tech Startup KrossLinker Develops a Cost-effective Aerogel Insulation
SINGAPORE, Feb. 2, 2023 /PRNewswire/ -- KrossLinker, an energy-efficiency-focused deep-tech advanced material startup, is designing and developing the world's most insulating nanomaterial, aerogel, that is low-cost, environmentally friendly, and scalable. Efficient and sustainable solutions fo...
2023-02-02 10:11
5855
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)
SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Invivoscribe is pleased to announce the appointment ofMasato Sasaki as General Manager of LabPMM GK, our reference laboratory inJapan. Mr. Sasaki brings a wealth of scientific experience with him as he served at Illumina K.K. (Japan) as a leader on their cl...
2023-02-02 05:00
3499
Global Times: Small and mid-sized cities in China go through infection peak, bearing new hope for future
BEIJING, Feb. 1, 2023 /PRNewswire/ -- As media sources around the world have paid so much attention to infection surges in various metropolises or first-and-second-tier cities inChina and governments at all levels have attached great importance to anti-epidemic work in rural areas, a review on ho...
2023-02-01 22:45
3283
Record short videos to assess Parkinson's disease, NERVTEX's First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved
WUHAN, China, Feb. 1, 2023 /PRNewswire/ -- NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other mo...
2023-02-01 22:08
2221
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...
2023-02-01 20:00
2656
Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that it is advancing the clinical development of...
2023-02-01 15:00
4961
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche L...
2023-01-31 21:50
4434
Global Times: 'So much better than we had anticipated': China's rural regions embrace Spring Festival as COVID peak ebbs away
BEIJING, Jan. 31, 2023 /PRNewswire/ -- The Spring Festival is rooted in agricultural civilization. Chinese people believe the most traditional atmosphere of Spring Festival is in rural regions. Since the prevention and control of the COVID-19 epidemic has entered a new stage, questions have been...
2023-01-31 21:41
3150
Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world's deadliest neglected diseases remained woefully inadequate and largely stagnant. Specific...
2023-01-31 21:30
2597
Guardant Health to integrate Lunit's AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection
* Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC * Lunit's AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health's portfolio of...
2023-01-31 21:05
3264
Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang...
2023-01-31 20:30
2722
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment inAustralia, the United States, and Italy * Presented compelling bioMUSE data at two prestigious industry conferences * Granted a 20-year patent for 100 new compounds targeting Parkinson's...
2023-01-31 20:25
5448
Mindray Unveils Next-generation BeneHeart Defibrillation Solutions to Raise Standards for Resuscitation
SHENZHEN, China, Jan. 31, 2023 /PRNewswire/ -- Mindray, a global leading medical device solutions provider, today announces the launch of next-generation BeneHeart series defibrillators, the BeneHeart D60 and D30. The new BeneHeart defibrillators aim to raise the standards for resuscitation with ...
2023-01-31 18:00
3699
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed t...
2023-01-31 17:40
4640
Week's Top Stories
Most Reposted
Cyient, 3-GIS Partner to Help Telecom and Utility Operators Turn Network Data into Operational Control
[Picked up by 1154 media titles]
2026-11-11 22:00Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1143 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1109 media titles]
2026-11-09 23:00
Poppi Founders Launch Hydration Brand jetty: NYSE Content Update
[Picked up by 1083 media titles]
2026-11-10 22:17
Most Read
DomoAI Launches InkoAI Agent - One Sentence to Ready-to-Post Video
2026-11-13 13:00
104880
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
27630
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
15903
